The company on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). CytRx Corporation (NASDAQ:CYTR) stock performance was -5.41% in last session and finished the day at $4.02. Traded volume was 9.62million shares in the last session and the average volume of the stock remained 1.84million shares. The beta of the stock remained 1.51. CytRx Corporation (NASDAQ:CYTR) insider ownership is 0.30%.

Trivascular Technologies Inc (NASDAQ:TRIV) unveiled in its quarterly report on 15 May 2014 that SG&A expenses for the three months ended March 31, 2014 were $12.2 million, compared to $7.5 million for the three months ended March 31, 2013, an increase of 62.5%. The increase in SG&A expenses was primarily associated with our initiation of Ovation System sales in the U.S. in November 2012 and the continued expansion of our U.S. commercial operations. Trivascular Technologies Inc (NASDAQ:TRIV) dropped -5.84 percent to $15.63 Friday on volume of 868,530.00million shares. The intra-day range of the stock was $15.32 to $17.27. Trivascular Technologies Inc (NASDAQ:TRIV) has a market capitalization of $316.64million.

Neuralstem (NYSE:CUR)‘s stock had its “outperform” rating reiterated by Zacks in a research note issued to investors on Wednesday. They currently have a $7.00 price target on the stock. Zacks‘s target price indicates a potential upside of 57.66% from the stock’s previous close. Neuralstem, Inc. (NYSEMKT:CUR)’s stock on June 27, 2014 reported a decrease of -6.08% to the closing price of $4.17. Its fifty two weeks range is $1.30 -$4.81. The total market capitalization recorded $361.80million. The overall volume in the last trading session was 6.47million shares. In its share capital, CUR has 86.76million outstanding shares.

On Tuesday, June 17, 2014, the NASDAQ Composite ended at 4,337.23, up 0.37%, the Dow Jones Industrial Average finished the day 0.16% higher at 16,808.49, and the S&P 500 closed at 1,941.99, up 0.22%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 688.85, down 0.07%, while the index has advanced 2.52% in the last one month. Investor-Edge has initiated coverage on the following equities: RadNet Inc. (NASDAQ: RDNT), IMS Health Holdings Inc. (NYSE: IMS), WuXi PharmaTech Cayman Inc. (NYSE: WX) and Ventrus Biosciences Inc. (NASDAQ: VTUS). On Friday, shares of Ventrus Biosciences Inc (NASDAQ:VTUS) dropped -6.94% to close the day at $1.34. Company monthly performance is recorded as 30.10%.  Ventrus Biosciences Inc (NASDAQ:VTUS) quarterly revenue growth is 6.35%.